Oncolytics Biotech  logo
Oncolytics Biotech ONCY
$ 0.92 -7.34%

Annual report 2024
added 12-13-2025

report update icon

Oncolytics Biotech Gross Profit 2011-2025 | ONCY

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Oncolytics Biotech

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - - - - - - - - -5.33 M

All numbers in CAD currency

Indicator range from annual reports

Maximum Minimum Average
-5.33 M -5.33 M -5.33 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-40.6 M $ 4.93 4.78 % $ 818 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
172 K $ 3.2 -1.69 % $ 247 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
4.31 M $ 1.07 -5.75 % $ 295 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
319 M $ 213.33 -3.22 % $ 5 B danmarkDanmark
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
177 K $ 3.13 -4.96 % $ 7.53 B australiaAustralia
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
1.12 M - -15.15 % $ 60.3 M britainBritain
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
374 M $ 26.45 4.67 % $ 1.28 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
103 M $ 9.6 0.37 % $ 141 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
2.03 M $ 0.26 -6.98 % $ 566 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
109 M $ 12.98 -7.91 % $ 854 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
319 K - -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
1.44 M - 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
1.24 B $ 548.58 -2.78 % $ 41.6 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
45.8 M $ 2.37 2.83 % $ 14.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
43.9 B $ 91.59 1.95 % $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
5.48 M $ 27.09 -1.53 % $ 1.74 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
1.82 K - -5.38 % $ 6.06 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
3.22 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
371 M $ 11.33 -1.78 % $ 733 M usaUSA
Biogen Biogen
BIIB
12.4 B $ 175.2 0.63 % $ 25.5 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
925 K $ 5.07 -5.5 % $ 108 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
301 M $ 87.67 -0.36 % $ 9.05 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
-493 K $ 1.43 -36.18 % $ 18.8 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
500 - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
53.8 M - -7.31 % $ 87 M usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
87.5 M $ 24.29 2.84 % $ 2.88 B usaUSA